Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $116.01 USD
Change Today -1.07 / -0.91%
Volume 10.2M
As of 8:10 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Norbert W. Bischofberger Ph.D.

Chief Scientific Officer and Executive Vice President of Research & Development, Gilead Sciences Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 1 different industries.

As of Fiscal Year 2014


Dr. Norbert W. Bischofberger, Ph.D, has been the Chief Scientific Officer of Gilead Sciences Inc. since March 9, 2007 and has been its Executive Vice President, Research and Development since November 2000. Dr. Bischofberger joined Gilead in 1990 as Director of Organic Chemistry and served as its Vice President of Organic Chemistry since February 1993 and Vice President of Research since August 1995. Dr. Bischofberger served as Senior Vice President Research at Gilead ...

Read Full Background

Corporate Headquarters*

333 Lakeside Drive
Foster City, California 94404

United States

Phone: 650-574-3000
Fax: 650-578-9264

Board Members Memberships*

There is no Board Members Memberships data available.


Post-Doctoral Training
Harvard University
Universität Innsbruck
Eidgenössische Technische Hochschule Zürich

Other Affiliations*

Annual Compensation*

Total Annual Compensation$920,647

Stock Options*

Restricted Stock Awards$2,905,986
All Other Compensation$8,820
Exercised Options540,000
Exercised Options Value$32,892,444
Exercisable Options1,277,082
Exercisable Options Value$92,149,165
Unexercisable Options227,658
Unexercisable Options Value$11,554,601
Total Value of Options$136,596,209
Total Number of Options2,044,740

Total Compensation*

Total Annual Cash Compensation$2,040,967
Total Short Term Compensation$920,647
Other Long Term Compensation$2,914,806
Total Calculated Compensation$6,794,187
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GILD:US $116.01 USD -1.07


Robert A. Bradway Chairman, Chief Executive Officer, President, Chairman of Executive Committee and Member of Equity Award Committee
Amgen Inc.
Omar S. Ishrak Chairman and Chief Executive Officer
Medtronic plc
Kenneth C. Frazier Chairman, Chief Executive Officer and President
Merck & Co. Inc.
Olivier Brandicourt Chief Executive Officer and Director
Richard A. Gonzalez Chairman, Chief Executive Officer and Chairman of Executive Committee
AbbVie Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GILEAD SCIENCES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at